Premium
Eruptive squamous cell carcinomas with keratoacanthoma‐like features in a patient treated with ruxolitinib
Author(s) -
Fabiano A.,
CalzavaraPinton P.,
Monari P.,
Moggio E.,
Pellacani G.,
Mangai A.M.,
Gualdi G.
Publication year - 2015
Publication title -
british journal of dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.304
H-Index - 179
eISSN - 1365-2133
pISSN - 0007-0963
DOI - 10.1111/bjd.13922
Subject(s) - ruxolitinib , myelofibrosis , medicine , keratoacanthoma , extramedullary hematopoiesis , dermatology , surgery , basal cell , bone marrow , stem cell , haematopoiesis , biology , genetics
Ruxolitinib is a JAK1 and JAK2 inhibitor, approved by the U.S. Food and Drug Administration (FDA) in November 2011, highly effective in the clinical management of myelofibrosis and associated complications (splenomegaly consequent to extramedullary hematopoiesis, cytopenias). We describe a case of Ruxolitinib-induced eruptive squamous cell carcinomas with keratoacanthoma-like features in a patient with myelofibrosis. A 74 year old woman was diagnosed with myelofibrosis in 2013 and was put on Ruxolinitib, without association of other immunosuppresive drugs. This article is protected by copyright. All rights reserved